KIT and gastrointestinal stromal tumor: Imatinib (Gleevec; Novartis), the tyrosine kinase inhibitor that targets activating mutations of c-kit, has been used in patients with gastrointestinal stromal tumors (GIST) harboring a c-kit exon 11 mutation.